137469-90-0

Basic information

• Product Name: 5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE
• Synonyms: 5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE;5-Nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine;5-Nitro-3,4-dihydro-2H-1,4-benzoxazine;5-Nitro-3,4-dihydro-2H-benzo[1,4]oxazine
• CAS NO: 137469-90-0
• Molecular Formula: C₈H₈N₂O₃
• Molecular Weight: 180.16
• Mol File: 137469-90-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE(137469-90-0)
• EPA Substance Registry System: 5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE(137469-90-0)

Safety Data

• Hazardous Substances Data: 137469-90-0(Hazardous Substances Data)

Usage

General Description

5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE is a chemical compound with a molecular formula C7H7NO4 that belongs to the benzoxazine class of compounds. It is classified as a nitrobenzoxazine due to the presence of a nitro group on the benzene ring. This chemical is used in the synthesis of various organic compounds and can act as a building block in the production of pharmaceuticals, agrochemicals, and other fine chemicals. 5-NITRO-2,3-DIHYDRO-1,4-BENZOXAZINE has the potential for various applications in the field of medicinal chemistry and may exhibit pharmacological properties that could be useful for the development of new drugs. However, it is important to handle this chemical with caution as it may pose health hazards if not used properly.

Upstream product

• 603-85-0 2-Amino-3-nitrophenol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 137469-91-1 3,4-dihydro-2H-benzo[b][1,4]-oxazin-5-amine 

Relevant articles and documents

High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators

We previously identified phenylquinoxalinone CFTRact-J027 (4) as a cystic fibrosis transmembrane conductance regulator (CFTR) activator with an EC50 of ～200 nM and demonstrated its therapeutic efficacy in mouse models of constipation. Here, structure-activity studies were done on 36 synthesized phenylquinoxalinone analogs to identify compounds with improved potency and altered metabolic stability. Synthesis of the phenylquinoxalinone core was generally accomplished by condensation of 1,2-phenylenediamines with substituted phenyloxoacetates. Structure-activity studies established, among other features, the privileged nature of a properly positioned nitro moiety on the 3-aryl group. Synthesized analogs showed improved CFTR activation potency compared to 4 with EC50 down to 21 nM and with greater metabolic stability. CFTR activators have potential therapeutic indications in constipation, dry eye, cholestatic liver diseases, and inflammatory lung disorders.

HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

The present specification provides a heterocyclic compound and an organic light emitting device using the same. The organic light emitting device comprises: a first electrode; a second electrode facing the first electrode; and one or more organic material layers including a light emitting layer formed between the first electrode and the second electrode, wherein the organic material layers comprise the heterocyclic compound.COPYRIGHT KIPO 2015

Synthesis of Bi- and Tri-cyclic Tetrazepinones

Diazotization of N,N'-dialkyl-N-(o-aminophenyl) ureas 7, 13 and 17 gave 3,5-dimethyl-3H-1,2,3,5-benzotetrazepin-4(5H)-one 8, 3-methyl-6,7-dihydro-1,2,3,5-tetrazepinoquinolin-4(3H)-one 14 and 3-methyl-6,7-dihydrooxazino-1,2,3,5-benzotetrazepin-4-one 19.The structures of these bi- and tri-cyclic systems were confirmed by 1H, 13C and 15N NMR data.X-Ray diffraction of compound 14 shows that the tetrazepinone ring is nonplanar.